Nantaporn Plurphanswat1, John R Hughes2, Karl Fagerström3, Brad Rodu1,4. 1. James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky. 2. Department of Psychiatry, Center for Behavior and Health, University of Vermont, Burlington, Vermont. 3. Fagerström Consulting, Vaxholm, Sweden. 4. Department of Medicine, School of Medicine, University of Louisville, Louisville, Kentucky.
Abstract
BACKGROUND AND OBJECTIVES: This is the first study to assess the appeal and interest among adults in a new consumer tobacco product, ZYN. We also describe ZYN users, patterns of use, and reasons for use. METHODS: Two data sets, consisting of a ZYN-naive consumer panel (n = 5179) and ZYN users (n = 1266), were provided by Swedish Match North America. Descriptive, cross-sectional analyses and logistic regression assessed the perceptions of and likelihood of buying ZYN in the consumer panel and the characteristics of ZYN users. RESULTS: The majority of current smokeless tobacco (ST) users in the consumer panel found that ZYN was moderately-extremely appealing, while never and former tobacco users indicated much less interest; the former were more likely to buy ZYN than other groups. The highest percentage of ZYN users were former tobacco users (43%); very few were never users (4%). The most popular reason for using ZYN was "Less harmful to my health than other tobacco products," followed by "ease of use." DISCUSSION AND CONCLUSIONS: Nonusers of tobacco had very little interest in ZYN. ST users are not only more interested and likely to buy ZYN than other tobacco users, they were the largest group of regular users. SCIENTIFIC SIGNIFICANCE: The first assessment of a new nicotine product, ZYN, suggests that current and former tobacco users may perceive ZYN as a reduced-risk product. ZYN potentially could be used as a smoking/tobacco-cessation aid based on reasons of current users. (Am J Addict 2020;00:00-00).
BACKGROUND AND OBJECTIVES: This is the first study to assess the appeal and interest among adults in a new consumer tobacco product, ZYN. We also describe ZYN users, patterns of use, and reasons for use. METHODS: Two data sets, consisting of a ZYN-naive consumer panel (n = 5179) and ZYN users (n = 1266), were provided by Swedish Match North America. Descriptive, cross-sectional analyses and logistic regression assessed the perceptions of and likelihood of buying ZYN in the consumer panel and the characteristics of ZYN users. RESULTS: The majority of current smokeless tobacco (ST) users in the consumer panel found that ZYN was moderately-extremely appealing, while never and former tobacco users indicated much less interest; the former were more likely to buy ZYN than other groups. The highest percentage of ZYN users were former tobacco users (43%); very few were never users (4%). The most popular reason for using ZYN was "Less harmful to my health than other tobacco products," followed by "ease of use." DISCUSSION AND CONCLUSIONS: Nonusers of tobacco had very little interest in ZYN. ST users are not only more interested and likely to buy ZYN than other tobacco users, they were the largest group of regular users. SCIENTIFIC SIGNIFICANCE: The first assessment of a new nicotine product, ZYN, suggests that current and former tobacco users may perceive ZYN as a reduced-risk product. ZYN potentially could be used as a smoking/tobacco-cessation aid based on reasons of current users. (Am J Addict 2020;00:00-00).
Authors: David Azzopardi; Linsey Ellen Haswell; Justin Frosina; Michael McEwan; Nathan Gale; Jesse Thissen; Filimon Meichanetzidis; George Hardie Journal: JMIR Res Protoc Date: 2022-10-06
Authors: Nicholas J Felicione; Liane M Schneller; Maciej L Goniewicz; Andrew J Hyland; K Michael Cummings; Maansi Bansal-Travers; Geoffrey T Fong; Richard J O'Connor Journal: Am J Prev Med Date: 2022-06-04 Impact factor: 6.604
Authors: Michael McEwan; David Azzopardi; Nathan Gale; Oscar M Camacho; George Hardie; Ian M Fearon; James Murphy Journal: Eur J Drug Metab Pharmacokinet Date: 2021-12-18 Impact factor: 2.441
Authors: David Azzopardi; James Ebajemito; Michael McEwan; Oscar M Camacho; Jesse Thissen; George Hardie; Richard Voisine; Gavin Mullard; Zvi Cohen; James Murphy Journal: Sci Rep Date: 2022-04-28 Impact factor: 4.996
Authors: Erin A Vogel; Jessica L Barrington-Trimis; Afton Kechter; Alayna P Tackett; Fei Liu; Steve Sussman; Caryn Lerman; Jennifer B Unger; Chanita Hughes Halbert; Benjamin W Chaffee; Adam M Leventhal Journal: Int J Environ Res Public Health Date: 2022-02-25 Impact factor: 4.614